Chemed vs BrightSpring Health Services, Inc. Common Stock: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chemed Corp (CHE)

Q3 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

August 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

Latest24 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

BrightSpring Health Services, Inc. Common Stock (BTSG)

Q3 20261 Aug – 16 Sep 2026

▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.
This is the core new operational driver behind the company's raised guidance and stock rally.
Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.
This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.
IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.
This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.
Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.
This is the key fundamental event that set the stage for the period's positive momentum.

August 20261 Aug – 16 Sep 2026

▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.
This is the core new operational driver behind the company's raised guidance and stock rally.
Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.
This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.
IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.
This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.
Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.
This is the key fundamental event that set the stage for the period's positive momentum.

Latest1 Aug – 16 Sep 2026

▲3▼1

BrightSpring's Specialty Pharmacy Boom Drives Earnings Outlook Higher

Specialty Pharmacy Growth Accelerates BrightSpring's specialty pharmacy revenue jumped 30% with scripts up 31%, driven by its limited distribution drug portfolio expanding to 155 programs and 12 new launches. This high-growth business is the main engine pushing BTSG's earnings and stock higher.
This is the core new operational driver behind the company's raised guidance and stock rally.
Analysts Raise 2026 Earnings Estimate Zacks lifted its 2026 EPS estimate by 16 cents to $1.82, implying 82% growth, and kept a Strong Buy rating. Higher profit expectations make the stock more attractive, pushing the price up.
This is a new analyst action that directly reflects improving fundamentals and influences investor sentiment.
IRA Pricing Pressure Persists BrightSpring expects the Inflation Reduction Act to cut Home and Community Pharmacy revenue by about $200 million in 2026 and Specialty and Infusion by $175 million, though EBITDA impact is minimal. This regulatory headwind caps revenue growth and weighs on sentiment.
This is a new regulatory update that quantifies ongoing revenue pressure, a real counterweight to the growth story.
Strong Q2 Results and Raised Guidance BrightSpring reported 23% revenue growth to $3.87 billion, adjusted EBITDA up 44%, and raised full-year revenue and EBITDA guidance. The strong quarter and improved outlook are the foundation for the stock's 59% year-to-date gain.
This is the key fundamental event that set the stage for the period's positive momentum.